One-Shot CRISPR treatment aims to cure lifelong blood disease
NCT ID NCT03655678
Summary
This study tested a one-time treatment for people with severe thalassemia, a genetic blood disorder requiring regular blood transfusions. Doctors used CRISPR gene-editing technology to modify a patient's own stem cells, then gave them back in a single infusion. The main goal was to see if this could allow patients to become free from transfusions for a year or more.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ann & Robert Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611, United States
-
British Columbia Children's Hospital
Vancouver, Canada
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Columbia University Medical Center (21+ years)
New York, New York, 10032, United States
-
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, United Kingdom
-
Lucile Packard Children's Hospital
Palo Alto, California, 94304, United States
-
Ospedale Pediatrico Bambino Gesù, IRCCS
Rome, Italy
-
Regensburg University Hospital, Clinic and Polyclinic for Paediatric and Adolescent Medicine
Regensburg, Germany
-
The Children's Hospital at TriStar Centennial Medical Center/ Sarah Cannon Center for Blood Cancers
Nashville, Tennessee, 37203, United States
-
The Hospital for Sick Children
Toronto, Canada
-
University College London Hospitals NHS Foundation Trust
London, United Kingdom
-
University Hospital Tübingen
Tübingen, Germany
-
Universitätsklinikum Düsseldorf Hospital Duesseldorf
Düsseldorf, Germany